https://www.selleckchem.com/products/cm-4620.html
therapy for the treatment of TNBC.Prophylactic donor lymphocyte infusion (pDLI) could reduce relapse in patients with refractory/relapsed acute leukemia (RRAL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), but optimal timing of pDLI remains uncertain. We compared the outcomes of two strategies for pDLI based on time from transplant and minimal residual disease (MRD) status in patients with RRAL. For patients without grade II-IV acute graft-versus-host disease (aGVHD) on day +60, pDLI was given on day +60 reg
Like
Comment
Share
